{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiviral+therapy", "query": { "intervention": "Antiviral therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 469, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiviral+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T15:37:20.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03208244", "title": "DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Heart Disease", "Hepatitis C" ], "interventions": [ { "name": "Clinically prescribed direct acting antiviral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-11-09", "completion_date": "2021-04-28", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03208244" }, { "nct_id": "NCT04452565", "title": "NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus Infection", "Severe Acute Respiratory Infection", "Severe Acute Respiratory Syndrome Coronavirus 2" ], "interventions": [ { "name": "Drug: NA-831", "type": "DRUG" }, { "name": "NA-831 and Atazanavir", "type": "COMBINATION_PRODUCT" }, { "name": "NA-831and Dexamethasone", "type": "COMBINATION_PRODUCT" }, { "name": "Atazanavir and Dexamethasone", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 525, "start_date": "2022-06-15", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2022-02-16", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 31, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04452565" }, { "nct_id": "NCT00000893", "title": "Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "16 Years", "sex": "ALL", "summary": "3 Months to 16 Years" }, "enrollment_count": 103, "start_date": "1997-10", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 25, "location_summary": "Long Beach, California • Los Angeles, California • Oakland, California + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000893" }, { "nct_id": "NCT00519792", "title": "Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Omega DUROS device", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2007-08", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519792" }, { "nct_id": "NCT00487188", "title": "A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Enfuvirtide", "type": "DRUG" }, { "name": "Highly active antiretroviral treatment (HAART)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2005-11", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Austin, Texas • Dallas, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487188" }, { "nct_id": "NCT01768286", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2013-01", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768286" }, { "nct_id": "NCT00000954", "title": "A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Zalcitabine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 72, "start_date": null, "completion_date": "1996-09", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000954" }, { "nct_id": "NCT00774397", "title": "Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335 NA 240 mg QD / LI", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI 201335 NA 120mg QD / LI", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg QD", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 719, "start_date": "2008-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774397" }, { "nct_id": "NCT02932150", "title": "Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 150, "start_date": "2016-11", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02932150" }, { "nct_id": "NCT00001989", "title": "A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Trichosanthin", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genelabs Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-10T15:37:20.760Z", "location_count": 8, "location_summary": "San Francisco, California • Miami, Florida • Tampa, Florida + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001989" } ] }